Buprenorphine/rss/search.php?qu=Buprenor/rss/search.php?qu=Buprenorphine/rss/search.php?qu=Buprenorphine RSS Page 7

Filtered By:
Drug: Dexamethasone

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 6494 results found since Jan 2013.

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research

ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283490. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory (RR)MM r...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Enrique M Ocio Yvonne A Efebera Roman H ájek Jan Straub Vladimir Maisnar Jean-Richard Eveillard Lionel Karlin Mar ía-Victoria Mateos Albert Oriol Vincent Ribrag Paul G Richardson Stefan Norin Jakob Oberm üller Nicolaas A Bakker Lud ěk Pour Source Type: research

Eosinophil recovery in hospitalized COVID-19 patients is associated with lower rates of ICU admission and in-hospital mortality: An observational cohort analysis
CONCLUSION: Trending eosinophil counts during hospitalization is simple and can be performed in resource-limited healthcare settings to track the inflammatory status of a patient. Lack of eosinophil recovery events can identify those at risk for future progression to severe COVID.PMID:37647739 | DOI:10.1016/j.resmer.2023.101031
Source: Respiratory Care - August 30, 2023 Category: Respiratory Medicine Authors: Peter D Yan Daniela Markovic Roxana Y Hixson Carolyn M Shover Russell G Buhr Ramin Salehi-Rad Blake LeMaster Donald P Tashkin Jennifer A Fulcher Igor Z Barjaktarevic Source Type: research

Corticosteroid implants for chronic non-infectious uveitis
CONCLUSIONS: Our confidence is limited that local corticosteroid implants are superior to sham therapy or standard-of-care therapy in reducing the risk of uveitis recurrence. We demonstrated different effectiveness on BCVA relative to comparators in people with non-infectious uveitis. Nevertheless, the evidence suggests that these implants may increase the risk of cataract progression and IOP elevation, which will require interventions over time. To better understand the efficacy and safety profiles of corticosteroid implants, we need future trials that examine implants of different doses, used for different durations. The...
Source: Cochrane Database of Systematic Reviews - August 29, 2023 Category: General Medicine Authors: Amit Reddy Su-Hsun Liu Christopher J Brady Pamela C Sieving Alan G Palestine Source Type: research

Oral cortisol and dexamethasone intake: differential physiology and transcriptional responses in the marine juvenile Sparus aurata
This study approached the long-term oral administration of cortisol (F) and dexamethasone (DEX), two synthetic glucocorticoids, compared to a control group (CT) in the juveniles of a marine teleost, the gilthead seabream (Sparus aurata). Physiologically, DEX treatment impaired growth, which appears to be linked to carbohydrate allocation in muscle and liver, hepatic triglycerides depletion, and reduced hematocrit. Hypophyseal gh mRNA expression was 2-fold higher in DEX than in CT or F groups. Similarly, hypothalamic trh and hypophyseal pomcb followed this pattern. Plasma cortisol levels were significantly lower in DEX than...
Source: General and Comparative Endocrinology - August 28, 2023 Category: Endocrinology Authors: A Barany J Fuentes V Valderrama A Broz-Ruiz G Mart ínez-Rodríguez J M Mancera Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20